Pfizer BioNTech gets Canada vaccine authorization
- Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) received Health Canada authorization for their Omicron XFG-adapted COVID-19 vaccine.
- The updated vaccine is expected to become available through distribution channels in the coming days and weeks.
- The authorization expands access to an updated COVID-19 vaccine formulation in Canada.
Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) received authorization from Health Canada for their Omicron XFG-adapted COVID-19 vaccine.
The authorization allows the updated vaccine formulation to be distributed in Canada, with Pfizer Canada stating that doses will become available through various distribution channels in the coming days and weeks.
The companies said the updated vaccine was developed to address the Omicron XFG variant, with availability dependent on distribution processes across Canada.
Pfizer and BioNTech developed COVID-19 vaccines through their partnership and continue to develop updated vaccine formulations based on circulating variants.
The Health Canada authorization follows regulatory reviews of updated COVID-19 vaccine formulations as public health agencies continue monitoring changes in circulating variants.
